Feature|Articles|October 15, 2024
- Pharmaceutical Executive: October 2024
- Volume 44
- Issue 10
Pharmaceutical Executive: October 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
Assembly Required: Building Blocks in Biopharmaover 1 year ago
Pharma’s Cold Calling: CGT Space at a Critical Crossroadsover 1 year ago
‘Selling a Vision’: Today’s Playbook for Startupsover 1 year ago
Rafaat Rahmani: Beating the Oddsover 1 year ago
AI: A Value Advantage? Maximizing Your Brand Outreachover 1 year ago
How to Rally a Team Around Building a New Businessover 1 year ago
Trading Quality for Convenience? The New Tech Balancing Actover 1 year ago
Amazon Targeting the Transactional in the Pharma MarketAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5